The Long Run with Luke Timmerman Podcast

The Long Run with Luke Timmerman

Timmerman Report
"The Long Run" Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous. Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Ep177: Kevin Parker on Finding Cancer Drug Targets
Kevin Parker, CEO of Cartography Biosciences, on finding new cancer drug targets.
Apr 14
58 min
Ep176: David Roblin on Building a TechBio Company
David Roblin, CEO of London-based Relation Therapeutics, on building a techbio discovery company.
Mar 31
1 hr 19 min
Ep175: Andy Scharenberg on in vivo CAR-T cell therapies
Andy Scharenberg, CEO of Seattle-based Umoja Biopharma, on developing in vivo CAR-T cell therapies.
Mar 16
1 hr 10 min
Ep174: Najat Khan on the TechBio Movement
Najat Khan, chief R&D and chief commercial officer of Recursion, on using technology to improve drug discovery.
Mar 3
1 hr 7 min
Ep173: Robert Blum on Building a Fully Integrated Biopharma For Muscle Disorders
Robert Blum, CEO of South San Francisco-based Cytokinetics, on building a fully integrated biopharma to treat muscle disorders.
Feb 11
57 min
Ep172: Mostafa Ronaghi on Studying Live Cells at Scale
Mostafa Ronaghi, co-founder and executive board member of Cellanome, on developing technology to look at live cells and cellular interactions at scale.
Jan 27
1 hr 20 min
Ep171: Ram Aiyar on RNA Editing Medicines
Ram Aiyar, CEO of Cambridge, Mass.-based Korro Bio, on RNA editing medicines.
Jan 13
1 hr 1 min
Ep170: David Schenkein on Investing in the Future of Biotech
David Schenkein, general partner at GV, on investing in the future of biotech.
Jan 2
59 min
Ep169: Kevin Fitzgerald on the Past & Future of RNAi Medicines
Alnylam Pharmaceuticals chief scientific officer Kevin Fitzgerald on the past, present & future of RNA interference medicines.
Dec 11, 2024
1 hr 2 min
Ep168: Jonathan Bricker on How to Quit Smoking & Prevent Cancer
Jonathan Bricker, professor in the cancer prevention program at Fred Hutchinson Cancer Center, on how to quit smoking with help from tech and biotech tools.
Nov 25, 2024
1 hr
Load more